Relationship of neurovascular elements to neuron injury during ischemia

Cerebrovascular Diseases

Volumn 27, Issue SUPPL. 1, 2009, Pages 65-76

  Del Zoppo, Gregory J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hemorrhagic transformation; Ischemic stroke; Neurons; Neurovascular unit; Proteases

Indexed keywords

[1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; ABCIXIMAB; ALTEPLASE; ANTICOAGULANT AGENT; COLLAGEN TYPE 4; DESMOTEPLASE; DISUFENTON SODIUM; FIBRONECTIN; GELATINASE A; GELATINASE B; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; KALININ; LAMININ 1; LUBELUZOLE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PLACEBO; PROUROKINASE; RECOMBINANT PLASMINOGEN ACTIVATOR; STREPTOKINASE; TIRILAZAD; UROKINASE;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; HUMAN; MICROVASCULATURE; NERVE CELL; NERVE CELL LESION; NERVE CELL NETWORK; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; STROKE;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CELL ADHESION MOLECULES; CEREBROVASCULAR CIRCULATION; EXTRACELLULAR MATRIX; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL HEMORRHAGES; MICROCIRCULATION; MICROVESSELS; MODELS, NEUROLOGICAL; NEURONS; NEUROPROTECTIVE AGENTS; PLASMINOGEN ACTIVATORS; STROKE;

EID: 64149104374     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000200442     Document Type: Conference Paper

References (90)

1. Iadecola C:Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004;5:347-360.
2. Zonta M, Angulo M, Gobbo S, et al:Neuronto-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci 2003;6:43-50.
3. Nedergaard M, Ransom BR, Goldman SA:New roles for astrocytes:redefining the functional architecture of the brain. Trends Neurosci 2003;26:523-530.
4. del Zoppo GJ, Mabuchi T:Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab 2003;23:879-894.
5. del Zoppo GJ, Milner R:Integrin-matrix interactions in the cerebral microvasculature. Arterioscler Thromb Vasc Biol 2006;26:1966-1975.
6. Liesi P:Do neurons in the vertebrate CNS migrate on laminin? EMBO J 1985;4:1163-1170.
7. Engvall E, Davis GE, Dickerson K, Ruoslahti E, Varon S, Manthorpe M:Mapping of domains in human laminin using monoclonal antibodies:localization of the neurite-promoting site. J Cell Biol 1986;103:2457-2465.
8. Herken R, Gotz W, Thies M:Appearance of laminin, heparan sulphate proteoglycan and collagen type IV during initial stages of vas-cularisation of the neuroepithelium of the mouse embryo. J Anat 1990;169:189-195.
9. David S, Braun PE, Jackson DL, Kottis V, McKerracher L:Laminin overrides the inhibitory effects of peripheral nervous system and central nervous system myelin-derived inhibitors of neurite growth. J Neurosci Res 1995;42:594-602.
10. Grant DS, Kleinman HK:Regulation of capillary formation by laminin and other components of the extracellular matrix. EXS 1997;79:317-333.
11. Bernstein JJ, Getz R, Jefferson M, Kelemen M:Astrocytes secrete basal lamina after hemisection of rat spinal cord. Brain Res 1985;327:135-141.
12. Hurwitz AA, Berman JW, Rashbaum WK, Lyman WD:Human fetal astrocytes induce the expression of blood-brain barrier specific proteins by autologous endothelial cells. Brain Res 1993;625:238-243.
13. Nagano N, Aoyagi M, Hirakawa K:Extracellular matrix modulates the proliferation of rat astrocytes in serum-free culture. Glia 1993;8:71-76.
14. Furuse M, Hirase T, Itoh M, et al:Occludin:a novel integral membrane protein localizing at tight junctions. J Cel l Biol 1993;123:1777-1788.
15. Itoh M, Nagafuchi A, Yonemura S, Kitani-Yasuda T, Tsukita S, Tsukita S:The 220-kD protein colocalizing with cadherins in non-epithelial cells is identical to ZO-1, a tight junction-associated protein in epithelial cells:cDNA cloning and immunoelectron microscopy. J Cell Biol 1993;121:491-502.
16. Furuse M, Itoh M, Hirase T, et al:Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol 1994;127:1617-162 6.
17. Furuse M, Sasaki H, Tsukita S:Manner of interaction of heterogeneous claudin species within and between tight junction strands. J Cell Biol 1999;14 7 :891-903.
18. Hurwitz AA, Berman JW, Rashbaum WK, Lyman WD:Human fetal astrocytes induce the expression of blood-brain barrier specific proteins by autologous endothelial cells. Brain Res 1993;625:238-243.
19. Mabuchi T, Lucero J, Feng A, Koziol JA, del Zoppo GJ:Focal cerebral ischemia preferentially affects neurons distant from their neighboring microvessels. J Cereb Blood Flow Metab 2005;25:257-266.
20. Bär T:Morphometric evaluation of capillaries in different laminae of rat cerebral cortex by automatic image analysis:changes during development and aging;in Cervos-Navarro J (ed):Advances in Neurology. New York , Raven Press, 1978, pp 1-9.
21. Bär T:The vascular system of the cerebral cortex. Adv Anat Embryol Cell Biol 1980;59:1-62.
22. Bär T:Patterns of vascularization in the developing cerebral cortex. Ciba Found Symp 1983;100:20-36.
23. Milner R, Hung S, Wang X, Spatz M, del Zoppo GJ:The rapid decrease in astrocyte-associated dystroglycan expression by focal cerebral ischemia is protease-dependent. J Cereb Blood Flow Metab 2008;28:812-823.
24. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ:Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 1995;26:2120-2126.
25. Carlson SS, Hockfield S:Central nervous system;in Comper WD (ed):Extracellular Matrix . Melbourne, Harwood Academic Publishers, 1996, vol 1, pp 1-23.
26. Webersinke G, Bauer H, Amberger A, Zach O, Bauer HC:Comparison of gene expression of extracellular matrix molecules in brain microvascular endothelial cells and astrocytes. Biochem Biophys Res Commun 1992;189:877-884.
27. del Zoppo GJ, Schmid-Schönbein GW, Mori E, Copeland BR, Chang CM:Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991;22:1276-1284.
28. Dore-Duffy P:Pericytes:pluripotent cells of the blood brain barrier. Curr Pharm Des 2008;14 :1581-1593.
29. Milner R, Hung S, Wang X, Berg GI, Spatz M, del Zoppo GJ:Responses of endothelial cell and astrocyte matrix-integrin receptors to ischemia mimic those observed in the neurovascular unit. Stroke 2008;39:191-197.
30. Haring HP, Akamine P, Habermann R, Koziol JA, del Zoppo GJ:Distribution of integrinlike immunoreactivity on primate brain microvasculature. J Neuropathol Exp Neurol 199 6;55:236-245.
31. Nouvel C, Caranobe C, Sie P, Capdeville J, Pris J, Boneu B:Platelet volume, density, and 5HT organelles (mepacrine test) in acute leukemia. Scand J Haematol 1978;21:421-426.
32. Hamann GF, Okada Y, del Zoppo GJ: Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 1996;16:1373-1378.
33. Wagner S, Tagaya M, Koziol JA, Quaranta V, del Zoppo GJ:Rapid disruption of an astrocyte interaction with the extracellular matrix mediated by integrin alpha 6 beta 4 during focal cerebral ischemia/reperfusion. Stroke 1997;28:858-865.
34. Tagaya M, Liu KF, Copeland B, et al:DNA scission after focal brain ischemia. Temporal differences in two species. Stroke 1997;28:1245-1254.
35. Tagaya M, Haring HP, Stuiver I, et al:Rapid loss of microvascular integrin expression during focal brain ischemia reflects neuron injury. J Cereb Blood Flow Metab 2001;21:835-846.
36. Abumiya T, Lucero J, Heo JH, et al:Activated microvessels express vascular endothelial growth factor and integrin alpha(v)beta3 during focal cerebra l ischemia. J Cereb Blood Flow Metab 1999;19:1038-1050.
37. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ:Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999;19:624-633.
38. Chang DI, Hosomi N, Lucero J, et al:Activation systems for matrix metalloproteinase-2 are upregulated immediately following experimental focal cerebral ischemia. J Cereb Blood Flow Metab 2003;23:1408-1419.
39. Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston LL, del Zoppo GJ:Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004;35:998-1004.
40. Derrick J, Shattil S, Poncz M, Gruppo R, Gartner T:Distinct domains of alphaIIbbeta3 support different aspects of outside-in signal transduction and platelet activation induced by LSARLAF, and alphaIIbbeta3 interacting peptide. Thromb Haemost 2001;86:894-901.
41. Lees KR, Barer D, Ford GA, et al:Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003;34:482-487.
42. Lees KR, Zivin JA, Ashwood T, et al:NXY059 for acute ischemic stroke. N Engl J Med 2006;354:588-600.
43. AstraZeneca:AstraZeneca announces SAINT II Trial Results Showed No Efficacy in Acute Ischaemic Stroke. 2006. http:// www.astrazeneca.com/ pressrelease/5279.aspx.
44. Shuaib A, Lees KR, Lyden P, et al:NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-571.
45. Koziol JA, Feng AC:On the analysis and interpretation of outcome measures in stroke clinical trials:lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke 2006;37:2644-2647.
46. Kontos CD, Wei EP, Williams JI, Kontos HA, Povlishock JT:Cytochemical detection of superoxide in cerebral inflammation and ischemia in vivo. Am J Physiol 1992;263:H1234-H1242.
47. Mohr J, Thompson J, Lazar R, et al:A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-1451.
48. The National Institutes of Neurological Disorders and Stroke rt-PA Stroke Study Group:Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
49. Robbins KC:The plasminogen-plasmin system;in Comerota AJ (ed):Thrombolytic therapy for peripheral vascu lar disease . Philadelphia, JB Lippincott, 1995, pp 41-65.
50. Rijken DC:Structure/function relationships of t-PA;in Kluft C (ed):Tissue Type Plasminogen Activator (t-PA):Physiological and Clinical Aspects. Boca Raton, CRC Press, 1988, vol 1, pp 101-122.
51. Ranby M, Bergsdorf N, Nilsson T:Enzymatic properties of the one- and two-chain form of tissue plasminogen activator. Thromb Res 1982;27:17 5-18 3.
52. Ranby M, Bergsdorf N, Norrman B, Svenson E, Wallen P:Tissue plasminogen activator kinetics;in Davison JF, Bachmann F, Bouvier CA, Kruithof EKO (eds):Progress in Fibrinolysis. New York, Churchill-Livingstone, 1982, vol 6, p 182.
53. Paoni N, Keyt B, Refino C, et al:A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA T103N, KHRR 296-299 AAAA. Thromb Haemost 1993;70:307-312.
54. Guzzetta AW, Basa LJ, Hancock WS, Keyt BA, Bennett WF:Identification of carbohydrate structures in glycoprotein peptide maps by the use of LC/MS with selected ion extraction with special reference to tissue plasminogen activator and a glycosylation variant produced by site directed mutagenesis. Anal Chem 1993;65:2953-2962.
55. Schleuning WD, Donner P:Desmodus rotundus (common vampire bat) salivary plasminogen activator;in Bachmann F (ed):Fibrinolytics and Antifibrinolytics . Berlin, Springer, 2001, pp 451-472.
56. Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning WD:Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992;79:1213-1217.
57. Gulba DC, Praus M, Witt W:DSPA alpha -properties of the plasminogen activators of the vampire bat Desmodus rotundus. Fibrinolysis 1995;9:91-96.
58. del Zoppo GJ, Poeck K, Pessin MS, et al:Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78-86.
59. Sato PH, Hall ED:Tirilazad mesylate protects vitamins C and E in brain ischemiareper fusion injur y. J Neurochem 1992;58:2263-2268.
60. Yamaguchi T:Intravenous rt-PA in acute embolic stroke;in Hacke W, del Zoppo GJ, Hirschberg M (eds):Thrombolytic Therapy in Acute Ischemic Stroke . Heidelberg, Springer, 1991, pp 168-174.
61. Mori E, Yoneda Y, Ohkawa S, Yoshida T, Ohsumi Y, Tabuchi M, Yamadori A, Kitano K, Tsutsumi A:Double-blind placebo-controlled trial of intravenous recombinant tissue plasminogen activator (rt-PA) in acute carotid stroke (abstract). Neurology 1991;41(suppl 1):347.
62. del Zoppo GJ, Ferbert A, Otis S, et al:Local intra-arterial fibrinolytic therapy in acute carotid territory stroke:a pilot study. Stroke 1988;19:307-313.
63. Mori E, Tabuchi M, Yoshida T, Yamadori A:Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988;19:802-812.
64. Hacke W, Kaste M, Fieschi C, et al:Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
65. Hacke W, Bluhmki E, Steiner T, et al:Dichotomized efficacy end points and global endpoint analysis applied to the ECASS intention-to-treat data set:post hoc analysis of ECASS I. Stroke 1998;29:2073-2075.
66. Hacke W, Kaste M, Fieschi C, et al:Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-1251.
67. Wahlgren N, Ahmed N, Davalos A, et al:Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST):an observational study. Lancet 2007;369:275-282.
68. Ueda T, Hatakeyama T, Kumon Y, Sakaki S, Uraoka T:Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT. Stroke 1994;25:298-303.
69. Larrue V, von Kummer R, del Zoppo GJ, Bluhmki E:Hemorrhagic transformation in acute ischemic stroke:potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957-960.
70. Larrue V, von Kummer RR, Muller A, Bluhmki E:Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator:a secondary analysis of the European-Australiasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-441.
71. del Zoppo GJ, Higashida RT, Furlan AJ, et al:PROACT:a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998;29:4-11.
72. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM: A pilotdose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005;36:607-612.
73. Hacke W, Albers G, Al-Rawi Y, et al:The Desmoteplase in Acute Ischemic Stroke Trial (DIAS):a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
74. Furlan AJ, Eyding D, Albers GW, et al:Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS):evidence of safety a nd efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-1231.
75. del Zoppo GJ, Copeland BR, Harker LA, et al:Experimental acute thrombotic stroke in baboons. Stroke 1986;17:1254-1265.
76. Young AR, Touzani O, Derlon JM, Sette G, MacKenzie ET, Baron JC:Early reperfusion in the anesthetized baboon reduces brain damage following middle cerebral arteryocclusion:a quantitative analysis of infarction volume. Stroke 1997;28:632-637.
77. Furlan AJ, Higashida R, Wechsler L, Schulz G;PROACT II Investigators:PROACT II:Recombinant Prourokinase (r-ProUK) in Acute Cerebral Thromboembolism:initial trial results - The PROACT II Investigators (abstract). Stroke 1999;30:202.
78. Fisher CM, Adams RD:Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 1951;10:92-94.
79. Fisher CM, Adams RD:Observations on brain embolism with special reference to hemorrhage infarction;in Furlan AJ (ed):The Heart and Stroke. Exploring Mutual Cerebrovascular and Cardiovascular Issues . New York, Springer, 1987, pp 17-36.
80. Abe T, Kazama M, Naito I, et al:Clinical evaluation for efficacy of tissue culture urokinase (TCUK) on cerebral thrombosis by means of multicenter double-blind study. Blood Vessel 1981;12:321-341.
81. Abe T, Kazawa M, Naito I, et al:Clinical effect of urokinase (60,000 units/day) on cerebral infarction - comparative study by means of multiple center double blind test. Blood Vessel 1981;12:342-358.
82. Atarashi J, Otomo E, Araki G, Itoh E, Togi H, Matsuda T:Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis:multi-center double-blind study in comparison with placebo. Clin Eval 1985;13:659-709.
83. Otomo E, Araki G, Itoh E, Tohgi H, Matuda T, Atarashi J:Clinical efficacy of urokinase in the treatment of cerebral thrombosis. Clin Eval 1985;13:711-751.
84. Otomo E, Tohgi H, Hirai S, et al:Clinical efficacy of AK-124 (tissue plasminogen activator) in the treatment of cerebral thrombosis:study by means of multi-center double blind comparison with urokinase. Yakuri To Chiryo 1988;16:3775-3821.
85. Abe T, Terashi A, Tohgi H, Sasoh S, Naito I:Clinical efficacy of intravenous administration of SM-9527 (t-PA) in cerebral thrombosis. Clin Eval 1990;18:39-69.
86. Haley EC Jr, Brott TG, Sheppard GL, et al:Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993;24:1000-1004.
87. The Multicenter Acute Stroke Trial - Europe Study Group:Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-150.
88. Donnan GA, Davis SM, Chambers BR, et al:Trials of streptokinase in severe acute ischaemic stroke. Lancet 1995;345:578-579.
89. Multicenter Acute Stroke Trial-Italy (MASTI) Group:Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-1514.
90. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D;ECASS Investigators:Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.